ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "macrophage activation syndrome"

  • Abstract Number: 813 • 2019 ACR/ARP Annual Meeting

    Monocyte and Macrophage Transcriptional Phenotypes in Systemic Juvenile Idiopathic Arthritis Reveal TRIM8 as a Mediator of IFNγ Hyperresponsiveness and Risk for Macrophage Activation Syndrome

    Grant Schulert1, Thuy Do 1, Sanjeev Dhakal 1, Ndate Fall 2, Mario Medvedovich 3, Sherry Thornton 1, Nathan salomonis 2 and Alexei A. Grom 1, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3University of Cincinnati College of Medicine, Cincinnati, OH

    Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe and distinct subtype of childhood arthritis. Children with SJIA are at risk for macrophage activation syndrome…
  • Abstract Number: 916 • 2019 ACR/ARP Annual Meeting

    Development and Initial Validation of the MS Score for Diagnosis of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis

    Francesca Minoia1, Francesca Bovis 2, Sergio Davì 3, AnnaCarin Horne 4, Michel Fischbach 5, Michael Frosch 6, Adam Huber 7, Marija Jelusic 8, Sujata Sawhney 9, Deborah McCurdy 10, Clovis Artur Silva 11, Donato Rigante 12, Erbil Unsal 13, Nicolino Ruperto 14, Alberto Martini 15, Randy Cron 16 and Angelo Ravelli 15, 1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Lombardia, Italy, 2Università degli Studi di Genova, Genoa, Italy, 3IRCCS Istituto Giannina Gaslini, Genova, Italy, 4Karolinska University Hospital, Stockholm, Sweden, 5Hopital Universitaire Hautepierre, Strasbourg, France, 6School of Medicine Witten/Herdecke University, Datteln, Germany, 7IWK Health Centre, Halifax, NS, Canada, 8University of Zagreb, Zagreb, Croatia, 9Sir Ganga Ram Hospital, New Delhi, India, 10University of California, MDCC 12-430, 10833 Le Conte Ave, Los Angeles, 90095, CA, USA, Los Angeles, 11Childrens’ Institute, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, 12Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 13Dokuz Eylul University, School of Medicie, Izmir, Turkey, 14Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 15IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, 16University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Macrophage activation syndrome (MAS) is the most severe complication of systemic juvenile idiopathic arthritis (sJIA) and its adult equivalent, adult-onset Still’s disease (AOSD).  Because…
  • Abstract Number: 917 • 2019 ACR/ARP Annual Meeting

    Systemic Juvenile Idiopathic Arthritis-Lung Disease: Characterization and Risk Factors

    Grant Schulert1, Shima Yasin 2, Brenna Carey 3, Claudia Chalk 3, Thuy Do 1, Andrew Schapiro 3, Ammar Husami 3, Allen Watts 3, Hermine Brunner 4, Jennifer Huggins 3, Elizabeth Mellins 5, Esi Morgan 3, Tracy Ting 3, Bruce Trapnell 6, Katheryn Wikenheiser-Brokamp 3, Christopher towe 3 and Alexei A. Grom 1, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 5Stanford University, Palo Alto, 6Cincinnati Children's Hospital, Cincinnati

    Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) is associated with a recently recognized albeit poorly defined and characterized lung disease (LD). Our objective is to describe…
  • Abstract Number: 1327 • 2018 ACR/ARHP Annual Meeting

    The Effect of Etoposide on Inducing Remission in Refractory Adult-Onset Still’s Disease: A Retrospective, Single-Center Study

    Haiting Wang1, Xiaodong Wang1, Ting Li1 and Shuang Ye2, 1Department of Rheumatology, Renji Hospital South Campus, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2Rheumatology, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, China

    Background/Purpose: Adult onset Still¡¯s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Macrophage activation syndrome (MAS) is a life-threatening complication and has been…
  • Abstract Number: 2900 • 2017 ACR/ARHP Annual Meeting

    Osteoarthritis-Associated Calcium-Containing Crystals and Biomaterial Microparticles Both Drive M1 Macrophage Polarization in a Syk and MAP Kinase-Dependent Manner

    Geraldine M. McCarthy1, Olwyn Mahon2, Sarah O'Hanlon3, Daniel Kelly4 and Aisling Dunne5, 1Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, 2School of Biochemistry and Immunology,, ,Trinity College Dublin, Dublin, Ireland, 3School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland, 4Trinity Center for Bioengineering, ,Trinity College Dublin, Dublin, Ireland, 5School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland

    Background/Purpose: Intra-articular basic calcium phosphate (BCP) crystals are associated with advanced osteoarthritis (OA) andsynovitis. OA-associated synovium exhibits increased numbers of macrophages compared with non-OA joints.…
  • Abstract Number: 4 • 2017 Pediatric Rheumatology Symposium

    Microbiota-Dependent Signals Regulate Inflammatory Myelopoiesis in a Murine Model of Macrophage Activation Syndrome

    Lehn K. Weaver1, Chhanda Biswas1, Niansheng Chu1 and Edward M. Behrens2, 1Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Targeting host-microbiota interactions to limit production of pathogenic myeloid cells that fuel chronic inflammatory responses is of therapeutic interest. Recent evidence suggests that this may…
  • Abstract Number: 187 • 2016 ACR/ARHP Annual Meeting

    Commensal Microbiota Tune Systemic Toll-like Receptor-Mediated Inflammatory Responses

    Lehn K. Weaver1, Chhanda Biswas1 and Edward M. Behrens2, 1Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Although commensal microbiota are thought to contribute to the development of autoimmunity, the cellular and molecular mechanisms connecting changes in gut microbiota to the…
  • Abstract Number: 2377 • 2016 ACR/ARHP Annual Meeting

    Innovative Use of PK and PD to Guide Dose Selection for a Monoclonal Antibody Aimed at Neutralizing the High IFNγ Activity Present in Patients with Macrophage Activation Syndrome (MAS)

    Philippe Jacqmin1, Kathy de Graaf2, Maria Ballabio2, Robert Nelson2, Zoë Johnson2, Walter Ferlin2, Geneviève Lapeyre2, Fabrizio De Benedetti3 and Cristina de Min2, 1MnS, Dinant, Belgium, 2NovImmune S.A., Geneva, Switzerland, 3Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy

    Background/Purpose: Data from an animal model of MAS and the observed high IFNγ and IFNγ-related chemokines (CXCL9, CXCL10) levels in MAS/sJIA patients have prompted the…
  • Abstract Number: 3005 • 2016 ACR/ARHP Annual Meeting

    Development and Initial Validation of the “MH Score”, a New Diagnostic Tool That Differentiates Primary Hemophagocytic  Lymphohistiocytosis from Macrophage Activation Syndrome

    Francesca Minoia1, AnnaCarin Horne2, Francesca Bovis1, Sergio Davì1, Laura Pagani1, Graciela Espada3, Gao Yi-Jin4, Antonella Insalaco5, Kai Lehmberg6, Helga Sanner7, Susan Shenoi8, Sheila Weitzman9, Nicolino Ruperto10, Alberto Martini1, Randy Q. Cron11 and Angelo Ravelli1, 1Istituto Giannina Gaslini, Genoa, Italy, 2Karolinska University Hospital Solna, Stockholm, Sweden, 3Hospital de Ninos Ricardo Gutierrez, Buenos Aires, Argentina, 4Children's Hospital of Fudan, Shanghai, China, 5Ospedale Pediatrico Bambino Gesù, Rome, Italy, 6University Medical Center, Hamburg, Germany, 7Norwegian National Advisory Unit on Rheumatic Diseases in Children and Adolescents, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, 8Seattle Children's Hospital, Seattle, WA, 9The Hospital for Sick Children, Toronto, ON, Canada, 10Pediatria II, Reumatologia, Istituto Giannina Gaslini, Genoa, Italy, 11University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: It is common view that macrophage activation syndrome (MAS) bears close similarities with primary hemophagocytic lymphohistiocytosis (pHLH). The resemblance of their clinical and laboratory…
  • Abstract Number: 404 • 2015 ACR/ARHP Annual Meeting

    Long-Term Outcomes of Macrophage Activation Syndrome in Childhood-Onset Systemic Lupus Erythematosus

    Roberto Ezequiel Borgia1, Maya Gerstein1, Deborah M. Levy2, Earl Silverman2 and Linda T Hiraki2, 1Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening inflammatory complication of childhood-onset systemic lupus erythematosus (cSLE). There are few reports of long-term outcomes of MAS complicating cSLE.…
  • Abstract Number: 2799 • 2014 ACR/ARHP Annual Meeting

    The Differential Impact of Obesity on the Pathogenesis of RA or Preclinical Models Is Contingent on the Disease Status  

    Zhenlong Chen1, Seung-jae Kim1, Abdul Essani2, Michael V. Volin3, Suncica Volkov1, William Swedler4, Shiva Arami2, Giamila Fantuzzi2, Nadera J. Sweiss5 and Shiva Shahrara1, 1Medicine/Rheumatology, University of Illinois at Chicago, Chicago, IL, 2University of Illinois at Chicago, Chicago, IL, 3Department of Microbiology and Immunology, Chicago College of Osteopathic Medicine Midwestern University, Downers Grove, IL, 4Section of Rheumatology, University of Illinois at Chicago, Chicago, IL, 5internal medicine section of rheumatology, University of Illinois at Chicago, Chicago, IL

    Background/Purpose: Studies were performed to determine the significance of obesity in the pathogenesis of rheumatoid arthritis (RA) and experimental arthritis models. Methods: Chronic and acute…
  • Abstract Number: 2199 • 2014 ACR/ARHP Annual Meeting

    Intravenous Immunoglobulin Therapy for Secondary Hemophagocytic Lymphohistiocytosis : A Retrospective Study of 46 Patients

    Bertrand Dunogué1, Magdalena Gerin2, Claire Larroche3, Catherine Montagnier-Petrissans4, Loïc Guillevin5 and Luc Mouthon5, 1Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, 2Internal Medicine, Hôpital Jean Verdier, Bondy, France, 3Internal Medicine, Hôpital Avicenne, Bobigny, France, 4Groupe d'Expert AP-HP, Paris, France, 5National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France

    Background/Purpose Intravenous Immunoglobulins (IVIg) have been reported as giving good results in infectious, but also auto-immune related forms of hemophagocytic lymphohistiocytosis (HLH), but only in…
  • Abstract Number: 2200 • 2014 ACR/ARHP Annual Meeting

    Elevated Serum Ferritin Levels in Adult Inpatients As a Predictor of in-Hospital Mortality and Association with Macrophage Activation Syndrome

    Matthew Mullen1, Marcin Trojanowski2, W. Winn Chatham3 and Bita Shakoory3, 1Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Medicine/ Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose Macrophage Activation Syndrome (MAS) is a syndrome similar to Familial Hemophagocytic Lymphohistiocytosis (HLH) characterized by increased proliferation and activity of T-cells and macrophages leading…
  • Abstract Number: 1243 • 2014 ACR/ARHP Annual Meeting

    Macrophage Activation Syndrome Complicating Adult Onset Still’s Disease – Single Center Experience and Literature Review

    Aleksander Lenert1 and Qingping Yao2, 1Orthopaedic and Rheumatologic Institute, Dept. of Rheumatic & Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 2Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a life threatening complication typically associated with hematologic malignancies and infections. HLH, also referred to as macrophage activation syndrome (MAS),…
  • Abstract Number: 2017 • 2013 ACR/ARHP Annual Meeting

    Hyper Ferritinemia Suggests a High Frequency Of Macrophage Activation Syndrome In a Large Adult Severe Sepsis Cohort: A Role For Anakinra?

    Bita Shakoory1, Joseph A. Carcillo2 and Steven Opal3, 1Medicine/Rheumatology, Temple University, Philadelphia, PA, 2Pediatrics, University of Pittsburg Medical Center, Pittsburgh, PA, 3Medicine, Brown University, Providence, RI

    Background/Purpose: Inreased ferritin levels are protective during infection whereas but very very high level are associated with MAS in rheumatologic disease cTo determine frequency of…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology